News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
740,569 Results
Type
Article (43906)
Company Profile (473)
Press Release (696178)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209982)
Career Advice (2064)
Deals (36210)
Drug Delivery (119)
Drug Development (84096)
Employer Resources (174)
FDA (16740)
Job Trends (15209)
News (355147)
Policy (33390)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2667)
Accelerated approval (36)
Adcomms (28)
Allergies (146)
Alliances (51214)
ALS (178)
Alzheimer's disease (1735)
Antibody-drug conjugate (ADC) (331)
Approvals (16977)
Artificial intelligence (549)
Autoimmune disease (161)
Automation (39)
Bankruptcy (373)
Best Places to Work (11848)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (654)
Cancer (4957)
Cardiovascular disease (418)
Career advice (1747)
Career pathing (38)
CAR-T (294)
CDC (46)
Celiac Disease (2)
Cell therapy (786)
Cervical cancer (36)
Clinical research (71558)
Collaboration (1806)
Company closure (4)
Compensation (1186)
Complete response letters (66)
COVID-19 (2779)
CRISPR (98)
C-suite (892)
Cystic fibrosis (152)
Data (6344)
Decentralized trials (2)
Denatured (39)
Depression (143)
Diabetes (505)
Diagnostics (6767)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (270)
Drug pricing (197)
Drug shortages (29)
Duchenne muscular dystrophy (245)
Earnings (91845)
Editorial (62)
Employer branding (21)
Employer resources (153)
Events (121314)
Executive appointments (1013)
FDA (19902)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1539)
Gene editing (214)
Generative AI (45)
Gene therapy (652)
GLP-1 (1011)
Government (4777)
Grass and pollen (6)
Guidances (384)
Healthcare (19254)
HIV (61)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (276)
Immuno-oncology (62)
Indications (111)
Infectious disease (3056)
Inflammatory bowel disease (199)
Inflation Reduction Act (17)
Influenza (119)
Intellectual property (254)
Interviews (319)
IPO (16957)
IRA (54)
Job creations (3725)
Job search strategy (1460)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (585)
Leadership (33)
Legal (8057)
Liver cancer (93)
Longevity (14)
Lung cancer (669)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (814)
MASH (171)
Medical device (13942)
Medtech (13995)
Mergers & acquisitions (20336)
Metabolic disorders (1322)
Multiple sclerosis (166)
NASH (19)
Neurodegenerative disease (342)
Neuropsychiatric disorders (97)
Neuroscience (3032)
Neurotech (1)
NextGen: Class of 2026 (6777)
Non-profit (4600)
Now hiring (67)
Obesity (633)
Opinion (284)
Ovarian cancer (168)
Pain (206)
Pancreatic cancer (235)
Parkinson's disease (296)
Partnered (34)
Patents (501)
Patient recruitment (507)
Peanut (57)
People (60487)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22502)
Phase 2 (31529)
Phase 3 (23332)
Pipeline (5365)
Policy (299)
Postmarket research (2614)
Preclinical (9625)
Press Release (67)
Prostate cancer (246)
Psychedelics (56)
Radiopharmaceuticals (300)
Rare diseases (897)
Real estate (6091)
Recruiting (71)
Regulatory (25092)
Reports (53)
Research institute (2505)
Resumes & cover letters (355)
Rett syndrome (27)
RNA editing (21)
RSV (78)
Schizophrenia (156)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (104)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3807)
State (2)
Stomach cancer (18)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1039)
Venture capital (95)
Weight loss (410)
Women's health (93)
Worklife (19)
Date
Today (33)
Last 7 days (518)
Last 30 days (2121)
Last 365 days (30697)
2026 (3600)
2025 (31116)
2024 (36343)
2023 (41068)
2022 (52331)
2021 (56799)
2020 (54985)
2019 (47552)
2018 (35785)
2017 (33086)
2016 (32425)
2015 (38484)
2014 (32250)
2013 (27212)
2012 (29364)
2011 (30012)
2010 (28190)
Location
Africa (759)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40801)
Australia (6774)
California (11526)
Canada (3316)
China (1146)
Colorado (487)
Connecticut (497)
Delaware (339)
Europe (89459)
Florida (1700)
Georgia (360)
Hawaii (3)
Idaho (61)
Illinois (887)
India (66)
Indiana (527)
Iowa (24)
Japan (438)
Kansas (130)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1418)
Massachusetts (8383)
Michigan (328)
Minnesota (641)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3068)
New Mexico (31)
New York (3034)
North Carolina (1537)
North Dakota (9)
Northern California (5607)
Ohio (338)
Oklahoma (21)
Oregon (45)
Pennsylvania (2309)
Puerto Rico (24)
Rhode Island (49)
South America (1126)
South Carolina (66)
South Dakota (1)
Southern California (4470)
Tennessee (175)
Texas (1772)
United States (41018)
Utah (341)
Vermont (1)
Virginia (268)
Washington D.C. (82)
Washington State (956)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
740,569 Results for "y mabs therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
August 6, 2025
·
15 min read
Press Releases
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
August 8, 2025
·
18 min read
Press Releases
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
August 8, 2025
·
1 min read
Business
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-mAbs Therapeutics, Inc. today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation.
March 14, 2024
·
6 min read
Business
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
Y-mAbs Therapeutics, Inc. announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.
June 5, 2024
·
7 min read
Pharm Country
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics, Inc. announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
April 25, 2024
·
8 min read
Pharm Country
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
Y-mAbs Therapeutics, Inc. today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.
December 13, 2023
·
5 min read
Press Releases
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
May 14, 2025
·
3 min read
Press Releases
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
May 13, 2025
·
21 min read
Business
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today reported financial results for the quarter and full year ended December 31, 2023.
February 29, 2024
·
17 min read
1 of 74,057
Next
